0001209191-23-002542.txt : 20230109
0001209191-23-002542.hdr.sgml : 20230109
20230109160438
ACCESSION NUMBER: 0001209191-23-002542
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220729
FILED AS OF DATE: 20230109
DATE AS OF CHANGE: 20230109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Race Geoffrey
CENTRAL INDEX KEY: 0001831607
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37718
FILM NUMBER: 23518113
MAIL ADDRESS:
STREET 1: C/O EDDEVA B920
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: F-star Therapeutics, Inc.
CENTRAL INDEX KEY: 0001566373
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 522386345
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 PARKWOOD DRIVE
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 44 1223 497400
MAIL ADDRESS:
STREET 1: 35 PARKWOOD DRIVE
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
FORMER COMPANY:
FORMER CONFORMED NAME: Spring Bank Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20130108
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-29
0
0001566373
F-star Therapeutics, Inc.
FSTX
0001831607
Race Geoffrey
C/O F-STAR THERAPEUTICS, INC.
EDDEVA B920, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE
X0
CB22 3AT
UNITED KINGDOM
1
0
0
0
Common Stock
2022-07-29
4
M
0
3937
0.11
A
3937
D
Stock Option (right to buy)
0.11
2022-07-29
4
M
0
3937
0.00
D
2029-12-18
Common Stock
3937
3937
D
This Report is reporting the exempt exercise of employee stock options for cash payment thereof and receipt of the resulting shares. No shares were sold incidental to the exercise of these stock options.
This exercise price was originally reported incorrectly as $0.08 per share due to a conversion rate error from Pound Sterling into U.S. Dollars. Using the August 2022 approximate exchange rate of 1.2211, the exercise price in U.S. Dollars would be approximately $0.11 per share.
Shall vest in 12 equal monthly installments so long as he remains a director of the company.
/s/ Darlene Deptula-Hicks, Attorney-in-fact
2023-01-09